{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318720292480.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1053/jhep.2001.26819"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2001.26819"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200109000-00018"}},{"identifier":{"@type":"NAID","@value":"30015126255"}}],"dc:title":[{"@value":"Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>Sustained viral suppression using monotherapy with interferon alfa (IFN-α) or lamivudine can only be achieved in a small percentage of patients with chronic hepatitis B. The concomitant administration of lamivudine and IFN-α does not enhance efficacy. We postulated that the optimal timing of therapy might be sequential treatment with lamivudine and IFN-α. The aim of this study was therefore to assess the efficacy of sequential treatment in patients resistant to IFN-α alone. Fourteen male patients, with a median age of 40 years, nonresponders to IFN-α with hepatitis B virus (HBV) DNA > 100 pg/mL (branched DNA [bDNA] Chiron) and positive hepatitis B e antigen (HBeAg) in 11 of 14 patients, were treated with lamivudine 100 mg/d alone for 20 weeks, then with both IFN-α2b 5 MU 3 times per week and lamivudine for 4 weeks, and lastly with IFN-α alone for 24 weeks. At the end of lamivudine therapy, all patients had undetectable serum HBV DNA, and none exhibited an emergence of HBV polymerase mutant or breakthrough. Sustained serum HBV-DNA clearance 6 months after the end of sequential treatment was achieved in 8 of 14 patients, HBeAg-to-anti-HBe seroconversion in 5 of 11 patients, and HBeAg and hepatitis B surface antigen (HBsAg) seroconversions in 3 of 14 patients (anti-HBs > 100 IU/mL). All sustained responders had normalized their alanine transaminase (ALT) values and exhibited histologic improvements. In conclusion, the results of this pilot study suggest that sequential treatment with lamivudine and IFN-α can induce a sustained virologic response, including HBs seroconversion, in patients with chronic hepatitis B not responding to IFN-α alone, without the selection of drug-resistant mutants. This therapeutic schedule warrants further evaluation in clinical trials. (Hepatology 2001;34:573-577.)</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380302175466851842","@type":"Researcher","foaf:name":[{"@value":"Lawrence Serfaty"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851845","@type":"Researcher","foaf:name":[{"@value":"Dominique Thabut"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851846","@type":"Researcher","foaf:name":[{"@value":"Fabien Zoulim"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851847","@type":"Researcher","foaf:name":[{"@value":"Tony Andreani"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851841","@type":"Researcher","foaf:name":[{"@value":"Olivier Chazouillères"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851843","@type":"Researcher","foaf:name":[{"@value":"Nicolas Carbonell"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851844","@type":"Researcher","foaf:name":[{"@value":"Alain Loria"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302175466851840","@type":"Researcher","foaf:name":[{"@value":"Raoul Poupon"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2001-09","prism:volume":"34","prism:number":"3","prism:startingPage":"573","prism:endingPage":"577"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2001.26819"},{"@id":"https://journals.lww.com/01515467-200109000-00018"}],"createdAt":"2002-08-25","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693139692416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617824940288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788892288","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Forefront of the viral chronic hepatitis treatment. Treatment of the case for which the treatment plans can not be decided. 2. Treatment of the case which is negative in HBe antigen and repeats liver function abnormality."},{"@value":"ウイルス性慢性肝炎治療の最先端―治療方針に迷う症例に対する治療―２．ＨＢｅ抗原陰性，肝機能異常を繰り返す症例に対する治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206399126784","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Indication of antiviral therapy for chronic hepatitis B"},{"@language":"ja","@value":"Ｂ型慢性肝炎の治療－Ｂ型肝炎治療のコンセンサスミーティングから"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206399687936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"核酸アナログ/IFN sequential治療の有用性とその限界"},{"@language":"en","@value":"Sequential therapy with a nucleos (t) ide analogue and interferon in patients with chronic hepatitis B: efficacy and limitations"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679767357696","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"ラミブジン短期投与中止後の急性増悪に対してＩＦＮ・ラミブジン併用療法が奏功したＢ型慢性肝炎の１例"},{"@language":"en","@value":"A Case of Chronic Hepatitis B Successfully Treated by the Combined Interferon-α/Lamivudine Therapy Against Acute Exacerbation Following the Cessation of the Initial Lamivudine Administration"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770184960","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Three cases of chronic hepatitis B in that interferon therapy was indicated"},{"@value":"インターフェロン治療を行ったB型慢性肝炎の3例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク インターフェロン チリョウ オ オコナッタ Bガタ マンセイ カンエン ノ 3レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770662656","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The efficacy of sequential treatment with lamivudine and alpha-interferon in anti-HBe-negative chronic hepatitis B patients -Examination of HBsAg seroclearance-"},{"@language":"ja","@value":"HBe抗原陰性B型慢性活動性肝炎に対するSequential療法の有用性―HBs抗原陰性化への検討―"},{"@language":"ja-Kana","@value":"HBe コウゲン インセイ Bガタ マンセイ カツドウセイ カンエン ニ タイスル Sequential リョウホウ ノ ユウヨウセイ : HBs コウゲン インセイカ エ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291226267478528","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700526864512","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Management of HBV infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975837321088","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1053/jhep.2001.26819"},{"@type":"CIA","@value":"30015126255"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.720_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1111/hepr.12488_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.853_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01707-6_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_F4lJxRmlnDSoiryFCMrsaej8DT9"}]}